RESUMO
BACKGROUND: Controversy surrounds the effect of alcohol consumption on the development of dementia and cognitive impairment. We investigated the association between consumption of different alcoholic beverages and ß-amyloid (Aß) aggregation in the brain, 1 of the neuropathological lesions of Alzheimer's disease. METHODS: In total, 125 males of the Helsinki Sudden Death autopsy Series were included with an age range at death 35 to 70 years. The consumption of alcohol, Aß aggregation in the brain, and Apolipoprotein E (APOE) genotype were assessed. Relatives answered a questionnaire to gather alcohol consumption history, and Aß was visualized by implementing immunohistochemical staining of brain sections. Aß immunoreactivity (IR) was assessed in a dichotomized (yes/no) fashion and as a stained area fraction (%). APOE genotype was assessed in DNA extracted from paraffin-embedded cardiac muscle samples. RESULTS: Increased age (p = 0.001; odds ratio [OR] = 1.09, confidence interval [CI] = 1.04 to 1.15) was associated with higher prevalence of Aß-IR. Beer drinking decreased (p = 0.024; OR = 0.35, CI = 0.14 to 0.87) the prevalence of Aß-IR and was associated with a significantly lower extent of Aß-IR (p = 0.022). The amount of alcohol consumed was not linked with Aß aggregation and neither was spirit nor wine consumption. CONCLUSIONS: Beer consumption may protect against Aß aggregation in brain. Further studies are necessary to fully understand the effects of alcohol on Aß pathology seen in brain tissue.
Assuntos
Consumo de Bebidas Alcoólicas/epidemiologia , Consumo de Bebidas Alcoólicas/metabolismo , Peptídeos beta-Amiloides/efeitos dos fármacos , Peptídeos beta-Amiloides/metabolismo , Cerveja , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Adulto , Fatores Etários , Idoso , Consumo de Bebidas Alcoólicas/genética , Apolipoproteínas E/genética , Autopsia , Encéfalo/patologia , Morte Súbita/epidemiologia , Finlândia/epidemiologia , Genótipo , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Ceratose Actínica/tratamento farmacológico , Ceratose Actínica/genética , Telomerase/genética , Idoso , Idoso de 80 Anos ou mais , Carcinoma in Situ/genética , Carcinoma de Células Escamosas/genética , Feminino , Humanos , Masculino , Mutação , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Regiões Promotoras Genéticas , Neoplasias Cutâneas/genéticaRESUMO
Empowering heliotherapy aims at clinical healing and improved coping with psoriasis and atopic dermatitis, but evidence of long-term effects is scarce. We studied the effect of 2-week empowering heliotherapy in the Canary Islands on clinical outcome and quality of life in 22 psoriasis and 13 atopic dermatitis patients. Empowerment consisted of meeting peers, sharing experiences and performing physical and mental practices. Using the self-administered PASI (SAPASI) psoriasis was alleviated statistically significantly during heliotherapy (p < 0.001), and the treatment effect was still detectable 3 months later (p < 0.001). Atopic dermatitis was improved (p < 0.001) when assessed with the patient-oriented SCORAD (PO-SCORAD), and the effect was still obvious 3 months later (p = 0.002). During heliotherapy the dermatology life quality index (DLQI) improved in both groups (p < 0.001), persisting in atopic patients for up to 3 months (p = 0.002), but not in psoriasis patients. In conclusion, a 2-week empowered heliotherapy showed a long-lasting improvement in psoriasis and atopic dermatitis disease activity, and also in the quality of life of atopic patients.